KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Work In Process (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Work In Process for 12 consecutive years, with $5.7 million as the latest value for Q1 2025.

  • Quarterly Work In Process changed N/A to $5.7 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Mar 2025, changed N/A year-over-year, with the annual reading at $5.5 million for FY2024, 14.89% down from the prior year.
  • Work In Process hit $5.7 million in Q1 2025 for ClearPoint Neuro, up from $5.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.5 million in Q4 2023 to a low of $1.6 million in Q1 2021.
  • Historically, Work In Process has averaged $3.9 million across 4 years, with a median of $3.9 million in 2021.
  • Biggest five-year swings in Work In Process: skyrocketed 34.21% in 2021 and later fell 14.89% in 2024.
  • Year by year, Work In Process stood at $2.3 million in 2021, then skyrocketed by 179.43% to $6.5 million in 2023, then dropped by 14.89% to $5.5 million in 2024, then grew by 2.73% to $5.7 million in 2025.
  • Business Quant data shows Work In Process for CLPT at $5.7 million in Q1 2025, $5.5 million in Q4 2024, and $6.5 million in Q4 2023.